Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.

Oncotarget - 15 Sept 2014

Wilson Catherine, Nicholes Katrina, Bustos Daisy, Lin Eva, Song Qinghua, Stephan Jean-Philippe, Kirkpatrick Donald S, Settleman Jeff

Abstract excerpt

Epithelial to mesenchymal transition (EMT) is a key process in embryonic development and has been associated with cancer metastasis and drug resistance. For example, in EGFR mutated non-small cell lung cancers (NSCLC), EMT has been associated with acquired resistance to the EGFR inhibitor erlotinib. Moreover, "EGFR-addicted" cancer cell lines induced to undergo EMT become erlotinib-resistant in vitro. To identify...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dasatinib
Share to Epithelial-Mesenchymal Transition

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Focal Adhesion Kinase 1

Share to Genes, erbB-1

Share to Quinazolines

Share to src-Family Kinases

Share to Thiazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 25193862
DOI: 10.18632/oncotarget.2397
PMCID: PMC4202126

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition.PMID 25193862Read ↗

Epithelial-to-mesenchymal transition is a resistance mechanism to sequential MET-TKI treatment of MET-amplified EGFR-TKI resistant non-small cell lung cancer cellsSemantic proximity Read ↗

Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib.Semantic proximity Read ↗

Focal adhesion kinase (FAK): emerging target for drug-resistant malignant tumorsSemantic proximity Read ↗

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.Semantic proximity Read ↗

RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.Semantic proximity Read ↗

Therapeutic strategies for afatinib‐resistant lung cancer harboring HER 2 alterationsSemantic proximity Read ↗

Dissecting signaling regulators driving AXL-mediated bypass resistance and associated phenotypes by phosphosite perturbationsSemantic proximity Read ↗

Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells.Semantic proximity Read ↗

Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.Semantic proximity Read ↗

The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated<i>EGFR</i>gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cellsSemantic proximity Read ↗

Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.Semantic proximity Read ↗

Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.